Every medtech founder eventually faces the same uncomfortable question: how do we talk about what this product does without overstepping what the FDA cleared us to say? Under-claim, and you waste the evidence you spent millions to generate. Over-claim, and you invite a warning letter, a stalled hospital deal, or both. FDA clearance proves your product is safe. Your documentation proves your company is trustworthy. Here's what U.S. hospitals actually evaluate before they buy.

FDA clearance is not the same thing as commercial readiness. In Step 1 of the MedTech Recovery Program, we break down why clinical data, KOL strategy, study design, and early site selection often fail to translate into real U.S. adoption. Learn how successful MedTech companies build commercially relevant evidence before entering hospital systems, Value Analysis Committees, and skeptical physician workflows.

FDA clearance is not a commercial strategy. It's permission to start building one. That distinction matters more than most international MedTech founders realize until they've already arrived in the U.S. market, pitch deck in hand, expecting momentum. What they find instead: Clinical skepticism Procurement committees Reimbursement walls Hospital IT And Decision-makers with zero emotional investment in their technology. Clearance doesn't protect you from any of that. Over the